Literature DB >> 11776412

Three case reports of the use of haemodiafiltration in the treatment of salicylate overdose.

G Wrathall1, R Sinclair, A Moore, D Pogson.   

Abstract

Aspirin (acetylsalicylic acid) is widely available without prescription. Although self-poisoning is rare, if severe it may be life threatening. Haemodialysis has been recommended in severe cases when salicylate levels exceed 7.3 mmol l(-1). We describe three cases of severe salicylate poisoning, which were treated with continuous veno-venous haemodiafiltration (CVVHDF). All patients survived. The first case had already undergone haemodialysis before transfer to the ICU, where CVVHDF was commenced because salicylism persisted at 3 mmol l(-1). A small reduction in serum salicylate was noted. In the second case, serum salicylate decreased from 8.5 to 3.5 mmol l(-1) after 3 h of CVVHDF even though only minimal urine was produced. Our third case is a chronic overdose in whom serum salicylate decreased from 6.2 to 4 mmol l(-1) after 4 h and to 1.4 mmol l(-1) after a further 7 h. No bicarbonate was administered to this patient and elimination can only be attributed to CVVHDF and urinary clearance, which is known to be slow. We discuss the pathogenesis of severe salicylate toxicity and postulate that CVVHDF, which is widely used in the intensive care setting, may be a useful therapy in severely poisoned patients who are unstable and cannot undergo haemodialysis or in situations where haemodialysis is unavailable.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11776412     DOI: 10.1191/096032701682693071

Source DB:  PubMed          Journal:  Hum Exp Toxicol        ISSN: 0960-3271            Impact factor:   2.903


  2 in total

1.  Modern Intermittent Haemodialysis (IHD) is an Effective Method of Removing Salicylate in Chronic Topical Salicylate Toxicity.

Authors:  Anselm Wong; Kathy Mac; Anders Aneman; Jeffrey Wong; Betty S Chan
Journal:  J Med Toxicol       Date:  2016-03

2.  Severe salicylate poisoning treated conservatively.

Authors:  Sandeep Basavarajaiah; Paul Sigston; Kuno Budack
Journal:  J R Soc Med       Date:  2004-12       Impact factor: 18.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.